TACE of liver metastases from colorectal cancer adopting irinotecan-eluting beads: Beneficial effect of palliative intra-arterial lidocaine and post-procedure supportive therapy on the control of side effects

Hepato-Gastroenterology

Volumn 55, Issue 88, 2008, Pages 2077-2082

  Fiorentini, Giammaria ^a   Aliberti, Camillo ^b   Benea, Giorgio ^b   Montagnani, Francesco ^a   Mambrini, Andrea ^c   Ballardini, Pier Luigi ^b   Cantore, Maurizio ^c  

^a SAN GIUSEPPE HOSPITAL   (Italy)

^b Hospital of the Delta   (Italy)

^c General City Hospital   (Italy)

Author keywords

Colorectal cancer; Hepatic angiography; Intra arterial lidocaine; Liver metastases

Indexed keywords

AMINOTRANSFERASE; ANTIEMETIC AGENT; CEFAZOLIN; DEXAMETHASONE; FLUOROURACIL; FOLINIC ACID; GLUCOSE; IRINOTECAN; LIDOCAINE; MORPHINE; OXALIPLATIN; RANITIDINE; SODIUM CHLORIDE; TROPISETRON;

ABDOMINAL PAIN; ACUTE PANCREATITIS; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BONE MARROW TOXICITY; CHEMOEMBOLIZATION; CLINICAL ARTICLE; COLORECTAL CANCER; DRUG ELUTING STENT; DRUG TOLERABILITY; EVENING DOSAGE; FEVER; GASTROINTESTINAL TOXICITY; HUMAN; HYDRATION; INFECTION; KIDNEY FAILURE; LENGTH OF STAY; LIVER ABSCESS; LIVER METASTASIS; MORNING DOSAGE; NAUSEA; NAUSEA AND VOMITING; PANCREAS DISEASE; PRIORITY JOURNAL; TREATMENT RESPONSE; VOMITING;

ABDOMINAL PAIN; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CHEMOEMBOLIZATION, THERAPEUTIC; COLORECTAL NEOPLASMS; INFUSIONS, INTRA-ARTERIAL; LIDOCAINE; LIVER NEOPLASMS; MICROSPHERES; PALLIATIVE CARE; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 60849105086     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Chong G, Cunningham D. Improving long-term outcomes for patients with liver metastases from colorectal cancer. J Clin Oncol 2005; 23:9063-9066.
2. Cohen AD, Kemeny NE. An update on hepatic arterial infusion chemotherapy for colorectal cancer. Oncologist 2003; 8:553-566.
3. Adam R, Avisar E, Ariche A, et al.: Five-years survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol 2001; 8:347-353.
4. Adam R. Chemotherapy and surgery: New prospectives on the treatment of unresectable liver metastases. Ann Oncol 2003 (suppl 2) 14:ii13-ii16.
5. Alberts SR, Horvath WL, Sternfeld WC, et al.: Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group Phase II study. J Clin Oncol 2005; 23:9243-9249.
6. Saltz LB, Cox JV, Blanke C, et al.: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer: Irinotecan Study Group. N Engl J Med 2000; 343:905-914.
7. Goldberg RM, Sargent DJ, Morton RF, et al.: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatica colorectal cancer. J Clin Oncol 2004; 22:23-30.
8. Hurwitz H, Fehrenbecher L, Novotny W, et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-2342.
9. Chen HX, Mooney M, Boron M, et al.: Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractoty colorectal cancer: an NCI treatment referral center trial TRC-0301. J Clin Oncol 2006; 24:3354-3360.
10. Cunningham E, Humblet Y, Siena S, et al.: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004; 351:337-345.
11. Machi J, Oishi AJ, Sumida K, et al.: Long-term outcome of radiofrequency ablation for unresectable liver metastases from colorectal cancer: evaluation of prognostic factors and effectiveness in first- and second-line management. Cancer J 2006; 12:318-326.
12. Berber E, Pelley R, Siperstein AE. Predictors of survival after radiofrequency thermal ablation of colorectal cancer metastases to the liver: a prospective study. J Clin Oncol 2005; 23:1358-1364.
13. Aliberti C, Tilli M, Benea G, Fiorentini G. Trans-arterial chemoembolization (TACE) of liver metastases from colorectal cancer using irinotecan-eluting beads: Preliminary results. Anticancer Res 2006; 26:3793-3796.
14. Morise Z, Sugioka A, Kato R, et al.: Transarterial chemoembolization with degradable starch microspheres, irinotecan, and mitomycin-C in patients with liver metastases. J Gastrointest Surg 2006; 10(2):249-258.
15. Fiorentini G, Rossi S, Bonechi F et al.: Intra-Arterial hepatic chemoembolization in liver metastases from neuroendocrine tumors: a phase II Study. J Chemotherapy 2004; 16:293-297.
16. Popov I, Lavrinc S, Jelic S, et al.: Chemoembolization for liver metastases from colorectal carcinoma: risk or benefit. Neoplasma 2002; 49:43-48.
17. Voigt W, Behrmann C, Schlueter A et al.: A new chemoembolization protocol in refractory liver metastasis of colorectal cancer: a feasibility study Onkologie 2002; 25:158-164.
18. Vogl TJ, Zangos S, Eichler K, et al.: Colorectal liver metastases: regional chemotherapy via transarterial chemoembolization (TACE) and hepatic chemoperfusion: an update. Eur Radiol 2007; 17:1025-1034.
19. Hunt TM, Flowerdrew AD, Birch SJ, et al.: Prospective randomized controlled trial of hepatic arterial embolization or infusione chemotherapy with 5-fluorouracil and degradable starch microspheres for colorectal liver metastases. Br J Surg 1990; 77:779-782.
20. Martinelli DJ, Wadler S, Bakal CW, et al.: Utility of embolization or chemoembolization as second-line treatment in patients with advanced or recurrent colorectal carcinoma. Cancer 1994; 74:1706-1712.
21. Salman HS, Cynamon J, Jagust M, et al.: Randomized phase II trial of embolization therapy versus chemoembolization therapy in previously treated patients with colorectal carcinoma metastatic to the liver. Clin Colorectal Cancer 2002; 2:173-179.
22. You Y-T, Changchien C-R, Huang J-S, et al.: Combining systemic chemotherapy with chemoembolization in the treatment of unresectable hepatic metastases from colorectal cancer. In J Colorectal Dis 2006; 21:33-37.
23. Fiorentini G, Aliberti C, Tilli M, Benea G: Transarterial chemoembolization (TACE) of liver metastases (LM) from colorectal cancer (CRC) using irinotecan-eluting beads. 2007 Gastrointestinal Cancers Symposium, Program/Proceedings page 261, Abstract 356.
24. Fiorentini G, Lucchi SR, Giovanis P, et al.: Irinotecan hepatic arterial infusion chemotherapy for hepatic metastases from colorectal cancer: results of a phase I clinical study. Tumori 2001; 87(6):388-390.
25. Fiorentini G, Rossi S, Dentico P, et al.: Irinotecan hepatic arterial infusion chemotherapy for hepatic metastases from colorectal cancer: a phase II clinical study. Tumori 2003; 89(4):382-384.
26. van Riel JM, van Groeningen CJ, Kedde MA, et al.: Continuous administration of irinotecan by hepatic arterial unfusion: a phase I and pharmacokinetic study. Clin Cancer Res 2002; 8:405-412.
27. Lewis AL, Gonzalez MV, Lloyd AW, et al.: DC Bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization. J Vasc Interv Radiol 2006; 17:335-342.
28. Taylor RR, Tang Y, Gonzalez MV, et al.: Irinotecan drug eluting beads for use in chemoembolization: in vitro and in vivo evaluation of drug release properties. Eur J Pharm Sci 2007; 30:7-14.
29. Tassinari D. Surrogate end points of quality of life assessment: have we really found what we are looking for? Health Qual Life Outcomes 2003; 24; 1:71-77.
30. Lee SH, Hahn ST, Park SH. Intraarterial lidocaine administration for relief of pain resulting from transarterial chemoembolization of hepatocellular carcinoma: its effectiveness and optimal timing of administration.Cardiovasc Intervent Radiol. 2001; 24(6):368-371.
31. Romano M, Giojelli A, Tamburrini O, Salvatore M. Chemoembolization for hepatocellular carcinoma: effect of intraarterial lidocaine in peri- and post-procedural pain and hospitalization Radiol Med (Torino). 2003; 105(4):350-355.
32. Hartnell GG, Gates J, Stuart K, Underhill J, Brophy DP. Hepatic chemoembolization: effect of intraarterial lidocaine on pain and postprocedure recovery. Cardiovasc Intervent Radiol. 1999; 22(4):293-297.
33. Huo TI, Wu JC, Lee PC, Chang FY, Lee SD. Incidence and risk factors for acute renal failure in patients with hepatocellular carcinoma undergoing transarterial chemoembolization: a prospective study.
34. Huo TI, Wu JC, Huang YH, Chiang JH, Lee PC, Chang FY, Lee SD. Acute renal failure after transarterial chemoembolization for hepatocellular carcinoma: a retrospective study of the incidence, risk factors, clinical course and long-term outcome.
35. Lopez-Benvtez R, Radeleff BA, Barragan-Campos HM, Noeldge G, Grenacher L, Richter GM, Sauer P, Buchler M, Kauffmann G, Hallscheidt PJ. Acute pancreatitis after embolization of liver tumors: frequency and associated risk factors. Pancreatology. 2007; 7(1):53-62.
36. Sakamoto I, Aso N, Nagaoki K, Matsuoka Y, Uetani M, Ashizawa K, Iwanaga S, Mori M, Morikawa M, Fukuda T, Hayashi K, Matsunaga N. Complications associated with transcatheter arterial embolization for hepatic tumors Radiographics. 1998; 18(3):605-619.
37. Vignaroli E, Pace EA, Willey J, Palmer JL, Zhang T, Bruera E The Edmonton Symptom Assessment System as a screening tool for depression and anxiety. J Palliat Med. 2006; 9:296-303.